Investor relations
Highlights
Total sales
2 207,8
11,4 %
100+
Financial calendar
Zinzino Interim report Q3 2025
Zinzino Delårsrapport Q3 2025
Year-End Report 2025
Bokslutskommuniké 2025
Zinzino Interim report Q1 2026
Zinzino Delårsrapport Q1 2026
Financial reports
Press releases
The stock
Zinzino Interim Report Q2 2025 – Interview
Carlsquare interviews CEO Dag Bergheim Pettersen about Zinzino’s Interim Report for Q2 2025.
Sustainability Report
Read more about our sustainability approach, targets and 2023 performance.
Elizabeta Sekulovska
shares@zinzino.com
+46 (0)763 066 954
Fredrik Nielsen
shares@zinzino.com
+46 (0)707 900 174
Certified Adviser
All companies whose shares are to be traded on the Nasdaq First North Premier Growth Market have a certified adviser who guides and supports the company through the listing process. Subsequently, the adviser monitors that the company complies with First North's regulations for providing information to the market and investors. DNB Carnegie Investment Bank AB (publ) is the Certified Adviser for Zinzino AB.
Certified Adviser:
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ)
Phone: +46 (0)738 564 265
E-mail: certifiedadviser@carnegie.se
Why invest in Zinzino
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
Distribuiți această pagină
Sau copiați conexiunea